CD47, also known as integrin-associated protein (IAP), is widely expressed on the surface of cells. CD47 can interact with inhibitory receptor signaling protein alpha (SIRPα), thrombospondin (TSP1), andintegrins mediating a series of reactions such as apoptosis, proliferation, and immunity [1, 2]. Studies haveconfirmed that CD47 molecules are over expressed in many malignant tumors, such as acute myeloidleukemia (AML), B-cell and T-cell acute leukemia, non-Hodgkin's lymphoma, and their expressionlevel negatively correlated with the prognosis of the disease. Tumor cells can escape the immune surveillanceof macrophage through the CD47-SIRPa signaling pathway. Therefore, blocking the binding of CD47toSIRPα by CD47 antibody can activate the phagocytosis of macrophage and the antigen presentation of DCcells. CD47 can combine with other immunotherapies to inhibit tumor growth [3,4]. GemPharmatech used the gene editing technology to replace the CD47 extracellular domainof BALB/c mice with the corresponding human fragments, and independently developed the BALB/c-hCD47humanized mouse model. This model completely preserves the intracellular portion of mouse CD47protein, ensuring normal intracellular signal transduction. This strain successfully expressed human CD47. BALB/c-hCD47 is an ideal animal model for evaluating the efficacy and safety of human CD47 inhibitors.